Biotech Values

[genisi]

Kamada's inhaled AAT phase 2/3 clinical trial in patients with Emphysema caused by Alpha-1 Antitrypsin (AAT) deficiency. The primary end point is exacerbation events and lung density:

http://clinicaltrials.gov/ct2/show/NCT01217671?term=kamada&rank=2